Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Aim(s): Using bi-shRNAimPDX-1 therapy in a mouse model of metastatic insulinoma to determine whether PDX-1 is a therapeutic target for insulinoma.
Materials and methods: Insulinoma (ß TC-6) cell proliferation and insulin secretion in vitro were determined by MTS and ELISA assay after bi-shRNAimPDX-1. In vivo therapy was performed on an i.p. ß TC-6 SCID mouse model with three bi-weekly cycles of iv liposomal(L)- bi-shRNAimPDX-1. Glucose and insulin levels and expression of islet cell PDX-1, insulin, PP levels, apoptosis and cell cycle proteins were determined. Survival analysis was performed using Kaplan-Meier (p<0.05).
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Dr F Charles Brunicardi
To read results and conclusion, please login ...
Further abstracts you may be interested in